---
title: 'Liquid biopsies and those three little words: finding the perfect match for
  the MTB'
date: '2024-06-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38835735/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240605181437&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Monitoring ctDNA by liquid biopsies seems to represent the perfect match
  for precision oncology and its cornerstone clinical framework: the molecular tumour
  board (MTB). Detecting and scrutinising the success of targeted therapies or tracking
  and, for that matter, addressing the therapy with the evolutive nature of a tumour
  are some of the main advancements one considers to be important for the MTB. One
  challenge is correlating the estimated allele frequency of each identified genetic
  ...'
disable_comments: true
---
Monitoring ctDNA by liquid biopsies seems to represent the perfect match for precision oncology and its cornerstone clinical framework: the molecular tumour board (MTB). Detecting and scrutinising the success of targeted therapies or tracking and, for that matter, addressing the therapy with the evolutive nature of a tumour are some of the main advancements one considers to be important for the MTB. One challenge is correlating the estimated allele frequency of each identified genetic ...